Fundraisings and IPOs

Date: 2018-09-20

Type of information: Private placement

Company: Fate Therapeutics (USA - CA)



Funding type: private placement

Planned used:

  • Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies, the manufacture of clinical product candidates and the conduct of preclinical research and development, and for general corporate purposes.


  • • On September 20, 2018, Fate Therapeutics announced the pricing of an underwritten public offering of 9,259,260 shares of its common stock at a public offering price of $13.50 per share, before underwriting discounts, for an aggregate offering of approximately $125.0 million. Fate Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,388,889 shares of its common stock. The proceeds to Fate Therapeutics from this offering are expected to be approximately $117.2 million after deducting underwriting discounts and commissions and other estimated offering expenses but excluding any exercise of the underwriters’ option. The offering is expected to close on or about September 25, 2018, subject to customary closing conditions.
  • • On September 20, 2018, Fate Therapeutics announced that it has commenced an underwritten public offering of its common stock.  All shares of common stock to be sold in the offering will be offered by Fate Therapeutics. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
  • Jefferies, Piper Jaffray, and Wells Fargo Securities are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as a co-manager for the offering.

Therapeutic area: Cancer - Oncology - Immunological diseases

Is general: Yes